34 2026 RNDS Леви: обновление по исследованию CosMOG (брендированное)

In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital, gave an update on the CosMOG trial, one of two large phase three trials in MOG antibody disease (MOGAD) [00:00:05]. He explained why preventing attacks matters and what people with a first MOGAD attack can expect [00:01:11]. He described how a MOGAD attack develops and how current medications act on different parts of the immune system [00:02:46]. Dr. Levy explained how the trial drug blocks FcRn so that antibodies are cleared faster, and how it compares with plasma exchange and IVIG [00:05:17]. He covered the trial design for people with relapsing MOGAD, in which everyone is allowed one attack before moving to open-label treatment, and said results may come by next year [00:10:29]. Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology. 00:00 Introduction 00:37 About the CosMOG Trial 01:11 Relapse Risk in MOGAD 01:45 Why Preventing Attacks Matters 02:46 How a MOGAD Attack Develops 04:14 How Current Medications Work 05:17 Blocking FcRn 07:53 How the Trial Began 08:53 Other MOGAD Trials 10:29 Trial Design 12:35 The Open-Label Phase and Safety 13:05 Where the Trial Stands